MedTrace Logo

HCC Surveillance: Comparison of Abbreviated Non-contrast MRI and Ultrasound Surveillance in Cirrhotic Patients With Suboptimal Ultrasound Visualisation

NCT04455932 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 476

Last updated 2021-09-08

No results posted yet for this study

Summary

All international guidelines recommend 6-monthly ultrasound surveillance for patients at risk for liver cancer (hepatocellular carcinoma or HCC), such as patients with cirrhosis. The aim of surveillance is to detect HCC at an early stage when it is still potentially curable. Currently only 4 out of 10 HCCs are detected at the early stage.

Ultrasound surveillance for HCC has a wide ranging sensitivity, dependent on many factors such as operator experience, patient body habitus and liver parenchymal heterogeneity due to chronic liver disease and cirrhosis. In a select group of patients, surveillance ultrasound can be suboptimal or near non-diagnostic.

Currently no guideline offers an alternative surveillance tool for patients who have suboptimal surveillance ultrasounds.

Conditions

Interventions

DIAGNOSTIC_TEST

Abbreviated non-contrast MRI of the liver

every 6 months

DIAGNOSTIC_TEST

Ultrasound surveillance

every 6 months

DIAGNOSTIC_TEST

Multiphase contrast-enhanced liver MRI

screening

Sponsors & Collaborators

  • Concord Repatriation General Hospital

    lead OTHER

Principal Investigators

  • Jessica Yang, MBBS · Concord Repatriation General Hospital

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-31
Primary Completion
2026-12-31
Completion
2027-03-31

Countries

  • Australia
  • New Zealand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04455932 on ClinicalTrials.gov